ACHIEVE LIFE SCIENCES, INC. (ACHV)

Insider Trading Filed: 2026-04-21

CEO Andrew D. Goldberg received a substantial equity grant totaling approximately 17.1 million shares/units (RSUs, stock options, and PRSUs combined) on 04/18/2026, representing a significant long-term incentive package tied to his continued service and performance.
The grant structure includes performance-based RSUs (PRSUs) with vesting tied to eight share price milestones ranging from 2x to 9x of a reference price, indicating management confidence in the company's growth potential and alignment of executive compensation with shareholder value creation.
The majority of the grant (11.7M shares) is contingent on achieving financial performance conditions through PRSUs, suggesting the board is using performance-based compensation to drive strategic objectives rather than providing guaranteed equity upside.
Stock options granted at $4.25 per share with a 10-year term show the company's current valuation reference point and provide upside participation only if the stock appreciates above this exercise price.

Current Report Filed: 2026-04-16

Achieve Life Sciences, Inc. has entered into a $180 million private placement with institutional and accredited investors to fund a Phase 3 clinical trial for their smoking cessation drug cytisinicline, as well as commercialization efforts.
The private placement includes the issuance of 49.4 million shares of common stock, pre-funded warrants, and common warrants that could provide an additional $173.8 million in proceeds if fully exercised.
The company has also entered into a registration rights agreement to register the resale of the shares issued in the private placement, providing liquidity for investors.

Current Report Filed: 2026-03-24

Achieve Life Sciences, Inc. reported its financial results for the fourth quarter and full year 2025, providing investors an update on the company's recent performance.
The press release indicates that the company's financial condition and operations remain stable, with no significant changes or surprises reported.
Overall, the filing appears to be a routine update on the company's financial performance, without any major events or developments that would significantly impact investors.

Annual Report Filed: 2026-03-24

The company has entered into a convertible debt agreement with Silicon Valley Bank, which could provide additional financing for operations.
Achieve Life Sciences has conducted several public offerings and private placements over the past few years, indicating a need for capital to fund its activities.
The company has a number of stock-based compensation plans in place, which could dilute existing shareholders if exercised or vested.

Insider Trading Filed: 2026-01-30

The reporting person, Jerry Wan, has been granted a stock option to acquire 70,300 shares of the issuer's common stock. This indicates potential insider confidence in the company's future.
The stock option has a 10-year term and will vest over a 4-year period, suggesting a long-term commitment from the reporting person.
As the Principal Accounting Officer, Jerry Wan's transaction could signal positive financial performance or growth prospects for the issuer, Achieve Life Sciences, Inc.

Insider Trading Filed: 2026-01-30

The reporting person, Richard Stewart, has been granted a stock option to acquire 645,000 shares of the issuer's common stock, which will vest over a 4-year period.
The option has an exercise price of $4.36 per share and a 10-year expiration date, indicating potential long-term alignment between the reporting person and the issuer.
This filing suggests continued leadership stability at the issuer, as the reporting person appears to maintain his role as Chief Executive Officer.

Insider Trading Filed: 2026-01-30

Craig Donnelly, the Chief Operations Officer of Achieve Life Sciences, Inc. (ACHV), has been granted a stock option to purchase 180,000 shares of the company's common stock, with a vesting schedule over 36 months.
This insider transaction suggests Donnelly's continued commitment to the company and aligns his interests with those of shareholders through his equity compensation.
The exercise price of $4.36 per share indicates the options were granted at the fair market value on the date of the grant, which is a common practice for incentive-based equity awards.

Insider Trading Filed: 2026-01-30

Jaime Xinos, the Chief Commercial Officer of Achieve Life Sciences, Inc. (ACHV), has been granted 180,000 stock options with an exercise price of $4.36 and a 10-year expiration date.
The options will vest over a 4-year period, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments thereafter, subject to Xinos' continued service.
This insider option grant suggests the company is providing long-term incentives to its executive leadership to align their interests with shareholders and drive the company's commercial success.

Insider Trading Filed: 2026-01-30

The reporting person, Mark K. Oki, who is the Chief Financial Officer of Achieve Life Sciences, Inc. (ACHV), has been granted a stock option to acquire 180,000 shares of the company's common stock.
The stock option has a grant date of January 28, 2026, an exercise price of $4.36 per share, and a 10-year expiration date.
The stock option will vest over a 4-year period, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in substantially equal monthly installments over the following 36 months, subject to the reporting person's continued service with the company.

Insider Trading Filed: 2026-01-30

The reporting person, Mark Lawrence Rubinstein, who is the Chief Medical Officer of Achieve Life Sciences, Inc. (ACHV), has been granted a stock option to acquire 180,000 shares of the company's common stock.
The stock option has an exercise price of $4.36 per share and will vest over a 4-year period, with 1/4 of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal monthly installments thereafter.
The insider transaction represents an investment in the company by a key executive, which could signal their confidence in the company's future prospects.

Important Information